Table 2.
Characteristics of Controls and Crohn’s Disease Subjects in Discovery, Replication and Combined Cohorts
| Characteristics | Discovery Cohort | Replication Cohort | Combined Cohorts | |||
|---|---|---|---|---|---|---|
|
| ||||||
| Controls, % (n = 542) | CD, % (n = 358) | Controls, % (n = 1,208) | CD, % (n = 416) | Controls, % (n = 1,750) | CD, % (n = 774) | |
| Sex | ||||||
| Male | 49.45 (268) | 53.35 (191) | 49.25 (595) | 56.49 (235) | 49.31 (863) | 55.04 (426) |
| Female | 50.55 (274) | 46.65 (167) | 50.75 (613) | 43.51 (181) | 50.69 (887) | 44.96 (348) |
| Ethnicity | ||||||
| French Canadian (caucasian) | 100.00 (542) | 75.70 (271) | 100.00 (1,208) | 100.00 (416) | 100.00 (1,750) | 88.76 (687) |
| Jewish | 15.92 (57) | 7.36 (57) | ||||
| Non caucasian | 8.38 (30) | 3.88 (30) | ||||
| Age, years | ||||||
| Range | 8.60 – 17.20 | 9.00 – 16.00 | 8.60 – 17.20 | |||
| Mean ± SD | 13.67 ± 2.72 | 12.71 ± 2.98 | 12.83 ± 2.90 | |||
| Age-at-onset, years | ||||||
| Range | 2.11 – 62.67 | 2.00 – 28.70 | 2.00 – 62.67 | |||
| Mean ± SD | 15.41 ± 7.63 | 12.69 ± 3.41 | 13.94 ± 5.90 | |||
| Disease Behavior | ||||||
| B1 ± p | 80.17 (287) | 87.74 (365) | 84.24 (652) | |||
| B2 ± p | 12.29 (44) | 6.01 (25) | 8.91 (69) | |||
| B3 ± p | 7.54 (27) | 6.25 (26) | 6.85 (53) | |||
| Disease Location | ||||||
| L1 ± L4 | 10.61 (38) | 21.63 (90) | 16.53 (128) | |||
| L2 ± L4 | 25.42 (91) | 29.81 (124) | 27.77 (215) | |||
| L3 ± L4 | 62.57 (224) | 48.08 (200) | 54.78 (424) | |||
| Only L4 | 1.40 (5) | 0.48 (2) | 0.90 (7) | |||
For the discovery cohort, patients were recruited from the inflammatory bowel disease clinics of tertiary pediatric and adult hospitals in Montreal. For the replication cohort, patients were recruited at the pediatric gastroenterology clinics of 3 hospitals across Canada (Montreal, Vancouver, Ottawa). Controls were obtained from the 1999 Quebec Child and Adolescent Health and Social Survey (QCAHSS). The designation of ethnicity was based on self-report. Disease location and behavior was classified according to World Gastroenterology Organization’s Montreal classification (L1, ileum; L2, colon; L3, ileocolon; L4, upper GI tract; B1, non-stricturing and non-penetrating; B2, structuring; B3, penetrating; p, perianal modifier). CD= Crohn’s disease.